Lite Strategy (LITS) EBITDA (2010 - 2026)
Lite Strategy (LITS) posted EBITDA of -$21.6 million for Q1 2026, up 27.65% on a QoQ basis from -$29.9 million in Q4 2025, and down 679.02% year-over-year from $3.7 million in Q1 2025.
Analysis
Lite Strategy (LITS) EBITDA (2010 - 2026) Analysis & Trends
Lite Strategy has reported EBITDA for 17 years, with the latest figure at -$21.6 million in Q1 2026.
- On a quarterly basis, EBITDA fell 679.02% year-over-year to -$21.6 million in Q1 2026; TTM through Mar 2026 was -$58.1 million, a 73.12% decrease from a year earlier, with the FY2025 full-year figure at -$17.5 million, down 220.03% from the prior year.
- EBITDA was -$21.6 million for Q1 2026 at Lite Strategy, up from -$29.9 million in the prior quarter.
- The five-year high for EBITDA was $55.3 million in Q3 2023, with the low at -$29.9 million in Q4 2025.
- Average EBITDA over 5 years is -$7.8 million, with a median of -$11.1 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: EBITDA soared 403.42% in 2023, then plunged 765.46% in 2025.
- Over 5 years, EBITDA stood at $8.9 million in 2022, then plunged by 233.65% to -$11.9 million in 2023, then jumped by 71.07% to -$3.5 million in 2024, then slumped by 765.46% to -$29.9 million in 2025, then rose by 27.65% to -$21.6 million in 2026.
- The last three EBITDA figures came in at -$21.6 million (Q1 2026), -$29.9 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | -21.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -21.61 Mn |
| Dec 31, 2025 | -29.87 Mn |
| Sep 30, 2025 | -3.74 Mn |
| Jun 30, 2025 | -2.88 Mn |
| Mar 31, 2025 | -2.77 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -18.98 Mn |
| Mar 31, 2024 | -9.83 Mn |
| Dec 31, 2023 | -11.93 Mn |
| Sep 30, 2023 | 55.28 Mn |
| Jun 30, 2023 | -11.08 Mn |
| Mar 31, 2023 | -16.39 Mn |
| Dec 31, 2022 | 8.93 Mn |
| Sep 30, 2022 | -18.22 Mn |
| Jun 30, 2022 | -16.20 Mn |
| Mar 31, 2022 | -21.56 Mn |
| Dec 31, 2021 | -17.63 Mn |
| Sep 30, 2021 | -20.11 Mn |
| Jun 30, 2021 | -15.47 Mn |